International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2025
Mental health, stigma and risk perception among early adopters of HIV PrEP with LA Cabotegravir in Italy: a multicenter cross-sectional and implementation study.
СтатьяМногоцентровое исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Del Duca Giulia, Moschese Davide, Maresca Martina, Fusetti Chiara, Esvan Rozenn, Cossu Maria Vittoria, Giacinta Alessandro, Lazzarin Samuel, Barchi Virginia, Caruso Francesco, Micheli Giulia, Gervasoni Cristina, Giacomelli Andrea, Antinori Andrea, Gori Andrea, Mazzotta Valentina
Аннотация
OBJECTIVES: Long-acting injectable cabotegravir (CAB-LA) offers an alternative to oral pre-exposure prophylaxis (PrEP), with potential benefits for adherence and stigma reduction. We investigated behavioral and psychosocial factors among early CAB-LA adopters in Italy, focusing on mental health, stigma, and prevention practices.
DESIGN OR METHODS: In a multicenter study, participants initiating CAB-LA completed baseline and follow-up questionnaires (weeks 4-20) assessing mental health, stigma, and prevention behaviors. Descriptive statistics summarized findings.
RESULTS: Of the 388 respondents, most (302, 89.2%) had prior experience with injectable medications, and 256 (75.9%) described these experiences positively. About half (198, 58.7%) reported recreational drug use, while 42 (12.4%) and 72 (21.3%) reported depressive and anxiety symptoms. Nearly one in four (78, 23.2%) were actively engaged in psychotherapy, while an additional 98 (28.9%) reported past engagement. Consistent condom use declined over time, with selective strategies increasing. A strong preference for biannual injections emerged (235, 69.8%), primarily administered in clinical settings (103, 30.5%). PrEP-related stigma was reported by 72 (21.3%) (strangers and friends as the most common sources), though some decline was observed during follow-up.
CONCLUSION: CAB-LA PrEP shows high acceptability, adherence, and evolving prevention practices. Although its discreet delivery may alleviate some concerns about visibility and disclosure, integration with mental health support and stigma-sensitive care is essential.
DESIGN OR METHODS: In a multicenter study, participants initiating CAB-LA completed baseline and follow-up questionnaires (weeks 4-20) assessing mental health, stigma, and prevention behaviors. Descriptive statistics summarized findings.
RESULTS: Of the 388 respondents, most (302, 89.2%) had prior experience with injectable medications, and 256 (75.9%) described these experiences positively. About half (198, 58.7%) reported recreational drug use, while 42 (12.4%) and 72 (21.3%) reported depressive and anxiety symptoms. Nearly one in four (78, 23.2%) were actively engaged in psychotherapy, while an additional 98 (28.9%) reported past engagement. Consistent condom use declined over time, with selective strategies increasing. A strong preference for biannual injections emerged (235, 69.8%), primarily administered in clinical settings (103, 30.5%). PrEP-related stigma was reported by 72 (21.3%) (strangers and friends as the most common sources), though some decline was observed during follow-up.
CONCLUSION: CAB-LA PrEP shows high acceptability, adherence, and evolving prevention practices. Although its discreet delivery may alleviate some concerns about visibility and disclosure, integration with mental health support and stigma-sensitive care is essential.